| Metric | Value ($ M) | vs Q2 FY25 |
|---|---|---|
| Revenue | 0.27 | 35.7% |
| Total Income | 0.27 | 35.7% |
| Expenditure | 3.47 | 11.9% |
| PBT | — | |
| Net Profit | -2.91 | 0.3% |
| OPM | — | |
| NPM | — | |
| EPS | -0.08 | 0.0% |
RenovoRx Reports Q3 2025 Financial Results, YTD Revenue at Approximately $900,000
04 May 2026 · 4 May, 7:17 am
Summary
RenovoRx announced its financial results for the third quarter ended September 30, 2025, reporting approximately $266,000 in revenue for the quarter and approximately $900,000 year-to-date. The company's cash and cash equivalents totaled $10.0 million as of September 30, 2025. RenovoRx is focused on expanding its commercial reach and advancing its Phase III TIGeR-PaC clinical trial, with enrollment expected to be completed in early 2026 and final data anticipated in 2027. The company believes its current cash position is sufficient to fund ongoing commercialization efforts and the completion of enrollment in its Phase III clinical trial.
Key Highlights
- 1
RenovoRx reported third quarter revenues of approximately $266,000.
- 2
Year-to-date revenue through Q3 2025 was approximately $900,000.
- 3
Cash and cash equivalents totaled $10.0 million as of September 30, 2025.
- 4
The company expanded from five cancer center customers at the start of 2025 to 14 customers as of November 7, 2025.
- 5
Research and development expenses were $1.7 million for the quarter ended September 30, 2025.
- 6
Net loss was $2.9 million for the quarter ended September 30, 2025, compared to a net loss of $2.5 million for the quarter ended September 30, 2024.
Management Comments
Shaun Bagai
“We continue to make strong progress both in our commercial and clinical activities,” said Shaun Bagai, CEO of RenovoRx. “On the commercial side, we are encouraged by the continued RenovoCath clinical adoption we are seeing in the field. Year-to-date revenue, through the end of the third quarter, was approximately $900,000, reflecting the growing clinical need and market demand for targeted drug-delivery solutions. Since organically launching commercial sales less than a year ago, we have expanded from five centers at the start of 2025 to 14 leading cancer centers now approved to purchase RenovoCath, including several that have already made repeat orders.” “With the recent hiring of Philip Stocton as Senior Director of Sales & Market Development and two regional sales managers, we are building the foundation for sustained growth while maintaining a lean operating structure and prudent capital deployment philosophy,” continued Mr. Bagai. “Our team remains laser-focused on strategic, data-driven expansion and is encouraged by the increasing physician-to-physician advocacy for our TAMP™ (Trans-Arterial Micro-Perfusion) platform as we continue to position RenovoRx for long-term success. Our mission continues with the goal of integrating an approach to therapeutic drug-delivery into the standard of care and ultimately improving patient outcomes by offering a more targeted and tolerable treatment path.” “On the clinical side, we continue to advance our Phase III TIGeR-PaC trial towards enrollment completion in early 2026 and final data readout in 2027, and we’ve successfully launched a new post-marketing registry study from which we expect to garner real-world evidence on the use of the RenovoCath device. We look forward to continuing our progress in the Phase III trial and post-market registry study as we seek to drive value for our shareholders,” concluded Mr. Bagai.
Informational and educational content only. Not investment advice.